Stifel analyst Annabel Samimy initiated coverage of Altimmune (ALT) with a Buy rating and $18 price target The company is developing next-generation peptide-based therapeutics with a novel GLP-1/glucagon dual agonist targeting the nexus of metabolic disease, obesity and dyslipidemia, and the firm contends that the next chapters in metabolic disease treatment will require innovation beyond the diabetes-obesity connection to address the numerous other related comorbidities of obesity, the analyst tells investors in a research note. Altimmune’s lead asset, pemvidutide/ALT-801, falls squarely in that trend, combining the potent weight-loss effects of GLP-1 with glucagon’s direct liver-targeted lipid metabolism, the firm adds.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALT:
- Largest borrow rate increases among liquid names
- Altimmune call volume above normal and directionally bullish
- Altimmune to be added to the Nasdaq Biotechnology Index
- Biotech Alert: Searches spiking for these stocks today
- Unusually active option classes on open December 4th
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
